Kisspeptin-10

The short answer

What is Kisspeptin-10?

Kisspeptin-10 is a ten-amino-acid peptide that acts on GnRH neurons in the hypothalamus, which is the top of the reproductive hormone axis rather than any point further down it. The first human work on the kisspeptin family used the longer kisspeptin-54 isoform and established that the hypothalamic-pituitary-gonadal axis responds to it in men (Dhillo et al., 2005). The decapeptide itself was then reported as a potent stimulator of luteinizing hormone, and to increase LH pulse frequency (George et al., 2011). A later study reported LH and serum testosterone responses in men with type 2 diabetes and mild biochemical hypogonadism, so the record is not confined to healthy volunteers (George et al., 2013). The groups are small and the work is early. Peptara supplies research-grade Kisspeptin-10 as a lyophilized 10mg vial for laboratory research; this page describes what published studies reported, not an effect in any person, and a qualified clinician is the only place a personal question belongs.

Applications

Common Research Areas

Evidence

What did the kisspeptin-10 studies measure?

Hormones, over short windows, in small groups. The decapeptide was reported as a potent stimulator of luteinizing hormone in men, with an increase in pulse frequency (George et al., 2011). A second study extended the question past healthy volunteers and reported LH and serum testosterone responses in men with type 2 diabetes and mild biochemical hypogonadism (George et al., 2013).

Two limits are worth stating rather than leaving implied. The human studies cited here delivered the peptide intravenously under monitoring (Dhillo et al., 2005; George et al., 2011), so their figures describe that setting and not another. And the endpoints were hormone measurements, not symptoms, function or outcomes over time; no trial here followed participants long enough to measure any of those. This page reports what was measured and stops there. Nothing on it is medical advice, and any route of administration in people is a decision for a licensed clinician.

How long the action lasted is part of that record. The decapeptide's LH rise followed an intravenous bolus rapidly, and the work that tracked pulse frequency ran a continuous infusion for up to 22.5 hours rather than repeating a bolus (George et al., 2011). For the longer isoform there is a measured figure: the 2005 study calculated a plasma half-life for kisspeptin-54 of 27.6 minutes (Dhillo et al., 2005). No half-life figure for the decapeptide appears in the three papers cited here, so none is stated on this page.

What the record does not contain is a safety dataset. These are small, short, controlled studies: six male volunteers in the kisspeptin-54 infusion study (Dhillo et al., 2005), groups of four to six men across the decapeptide bolus and infusion arms (George et al., 2011), and five men with type 2 diabetes alongside seven age-matched healthy men in a study its authors described as proof of concept (George et al., 2013). Their published endpoints are hormone concentrations, not long-term tolerability, and this page does not present them as more than that.

The certificate for this batch is pending. Fourteen of the nineteen catalog SKUs carry a published third-party panel today, listed on the certificates page, and the remaining five say pending rather than showing a figure no lab has measured.

Kisspeptin-10 FAQ